The NCI Director’s Intramural Innovation Award Program is designed to support development of highly innovative approaches and technology aimed at significant cancer-related problems. Novel proposals with the potential for high impact, the potential to generate new intellectual property or technology, or which are considered too high-risk or preliminary to pursue within the base budget allocation are encouraged. Proposals with an emphasis on health disparities research are also encouraged. The program offers one-time awards at two levels: Principal Investigator (PI) Awards are targeted to tenure-track PIs, recently tenured PIs (within 5 years of tenure), and CCR Senior Scientists/Clinicians, with an upper limit of $50,000; Career Development Awards are targeted to Postdoctoral Fellows, Staff Scientists, and Staff Clinicians at all levels, with an upper limit of $10,000.
The next round of innovation award submission is tentatively scheduled to open during the summer of 2013.
Luca Gattinoni, M.D., Experimental Transplantation and Immunology Branch
Enhancing the Efficacy of Adoptive T Cell-based Therapies in Lymphoreplete Hosts
Claudia Palena, Ph.D., Laboratory of Tumor Immunology and Biology
Immunological Approaches to Target the Epithelial-Mesenchymal Switch of Human Carcinomas
Kandice Tanner, Ph.D., Laboratory of Cell Biology
Mechanical Regulation of the Microenvironmental Niche in Skin Tumorigenesis
John Schneekloth, Jr., Ph.D., Chemical Biology Laboratory
A Multiparallel Approach to Ubiquitin E2 Enzyme Profiling and Inhibitor Discovery Using Microarrays
Daniel Abate-Daga, Ph.D., Surgery Branch
Analysis of Anti-Tumor Antibodies Produced by Tumor-Infiltrating B Cells
Michael Armani, Ph.D., Laboratory of Pathology
Tablet Microdissection
Romi Biswas, Ph.D., Molecular Oncology Branch
Mouse Models to Study the Role of Expression Level of Mutant EGFR Oncogene in Lung Tumorigenesis
Nicolas Cuburu, Ph.D., Laboratory of Cellular Oncology
Harnessing Established Anti-Viral Immunity for the Treatment of Cancer
Natalay Kouprina, Ph.D., Laboratory of Molecular Pharmacology
A New Assay for Measuring Chromosome Instability (CIN) and Identification of Drugs Elevating CIN
Xi Liu, Ph.D., Laboratory of Cellular Oncology
Establish Cervical Cancer Mouse Model by Lentiviral Gene Delivery
Michael Lizardo, Ph.D., Pediatric Oncology Branch
Adaptation to ER Stress in the Lung Microenvironment Is a Hallmark of the Metastatic Phenotype
Yong-Chen William Lu, Ph.D., Surgery Branch
Identification of Novel Mutated T-Cell Antigens by Minigene Libraries Based on Exome Sequencing Data
Thomas G. Magaldi, Ph.D., Laboratory of Cellular Oncology
Horizontal Transfer of Host Cell Genomic DNA by the Capsids of Non-Enveloped dsDNA Viruses
Tapan Kumar Maity, Ph.D., Molecular Oncology Branch
Translational Regulation of Mutant EGFR Targets That Are Altered Upon TKI Treatment
Michael L. Nickerson, Ph.D., Laboratory of Experimental Immunology
Association of Somatic Alterations in Clear Cell Kidney Tumors
Ty C. Voss, Ph.D., Laboratory of Receptor Biology and Gene Expression
Development of High-Throughput Single Molecule RNA Fluorescence In Situ Hybridization Methods
Marcin Walkiewicz, Ph.D., Laboratory of Receptor Biology and Gene Expression
Target Recognition by Atomic Force Microscopy Using Antibody Conjugated Quantum Dots (TRAQ-DOTS)
Willie Wilson III, Ph.D., Laboratory of Cancer Biology and Genetics
Predictive Melanoma Biomarker Assay Development for Anti-CTLA-4 (Ipilimumab) Therapy
A service of the National Cancer Institute
